




SUPPLEMENTARY FIGURES




Supplementary Figure 1. Chemical structure of catalpol.




Supplementary Figure 2. Catalpol inhibited hepatic steatosis and cell apoptosis in hepG2 cells. (A) Catalpol inhibited hepatic steatosis in oxLDL-treated hepG2 cells. (B) Catalpol inhibited hepatic steatosis in PA-treated hepG2 cells. (C) Catalpol inhibited apoptosis in PA-treated hepG2 cells.



Supplementary Figure 3. Food intake of the mice. The results are the mean \pm SD (n=8).



Supplementary Figure 4. P66shc and cyto C protein expressions in oxLDL-treated hepG2 cells. (A) P66shc protein expression. (B) cyto C protein expression. The results are the mean \pm SD (n=8), **P < 0.05 vs. Control group, ##P < 0.05 vs. oxLDL group.



Supplementary Figure 5. Antagomir-96-5p aggregated PA-induced hepatic steatosis and oxidative stress. (A) miR-96-5p level. **(B)** P66Shc protein expression. **(C)** Cyto C protein expression. **(D)** Nile red staining. **(E)** ROS level. The results are the mean \pm SD (n=8), **P < 0.05 vs. Control group, ##P < 0.05 vs. PA group.